Sitting for over 10 hours or more a day is significantly linked to future heart failure and cardiovascular death risk, a new ...

Valuable data can successfully be collected with the noninvasive wearable, which is worn on the sternum, report investigators ...

Both the nasal and IV forms of bumetanide had a variability in absorption of 27%, suggesting a more stable route of dosing ...

The combination of sacubitril and valsartan reduces the cardiotoxicity related to anthracycline chemotherapy drugs, according ...

She was 64 A cause of death has been revealed for Tyka Nelson, the younger sister of Prince Rogers Nelson, professionally ...

We know that exercise is good for our hearts and overall health. But is that true for people living with heart failure? And ...

New research highlights how air pollution exacerbates heart failure, revealing increased inflammation and the need for ...

Tirzepatide is a long-acting dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist ...

Of the patients who received the treatment, many of who had advanced symptoms of heart failure at the beginning of the study, ...

The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

A new nasal spray form of the medication bumetanide may reduce the tissue swelling caused by heart failure as effectively as the standard oral and intravenous formulations of the medication, according ...

Reducing systolic blood pressure to less than 120 mmHg lowered the risk of major cardiovascular events for most people with ...